Core Viewpoint - Heng Rui Medicine (600276)(01276) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, which will commence shortly [1] Group 1: Product Development - SHR-A2009 is an antibody-drug conjugate targeting HER3, specifically binding to HER3 on the surface of tumor cells [1] - The drug is designed to be internalized by the tumor cells and transported to lysosomes, where it releases free toxins to kill the cancer cells [1] - No similar drugs have been approved for market globally, indicating a potential first-mover advantage for the company [1]

HRS-7172 片是公司自主研发的新型抗肿瘤小分子抑制剂。经查询，目前国内外尚无同类药物获批上 市。截至目前，HRS-7172 片相关项目累计研发投入约 2,841 万元。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，该公司收到国家药品监督管理局(以下简称"国家药 监局")核准签发关于 HRS-7172 片的《药物临床试验批准通知书》，将于近期开展临床试验。 ...

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor developed by the company [1] Group 1: Product Development - HRS-7172 tablets are a novel anti-tumor small molecule inhibitor independently developed by the company [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million yuan [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, a novel antibody-drug conjugate targeting HER3 [1] Company Summary - SHR-A2009 is designed to specifically bind to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1] - This drug is notable as there are currently no similar drugs approved for market globally [1]

Macro Dynamics - The China-Shanghai Cooperation Organization Green Industry Cooperation Platform was officially launched in Tianjin, aiming to enhance dialogue, promote practical project cooperation, and strengthen green standards alignment among member countries [2] - The platform will focus on integrating green industry supply chains and facilitating the joint research and promotion of advanced green technologies [2] Software Industry - In the first seven months of 2025, China's software and information technology services industry reported a total profit of 108.9 billion yuan, reflecting a year-on-year growth of 12.4% [3] - Software business revenue reached 832.46 billion yuan, with a year-on-year increase of 12.3%, while software exports amounted to 33.98 billion USD, growing by 5.2% [3] Real Estate - Hunan Yueyang launched a housing subsidy program offering up to 200,000 yuan for home purchases in designated urban areas, effective from September 1 to November 15, 2025 [4][5] Financial Institutions - Xun Yugen has been appointed as the Chief Economist and Director of the Economic Research Institute at Guosen Securities, bringing 18 years of experience in securities research [7] - The Finance Minister of Pakistan, Aoran Zeb, visited the Industrial and Commercial Bank of China to discuss macroeconomic conditions and deepen economic and financial cooperation [8] - China Life Insurance's subsidiary has invested 1 billion yuan in a newly established venture capital fund focused on private equity investments [9] Market Data - The Shanghai Composite Index fell by 0.45%, with significant declines in the CPO concept and a strong performance in the banking sector [10] - The total margin financing balance across both exchanges increased by 35.396 billion yuan, reaching 2.273496 trillion yuan [11] Company Dynamics - Tianpu Co., Ltd. announced a potential suspension of trading due to significant stock price fluctuations, with an accumulated increase of 100% over eight consecutive trading days [14] - Western Gold reported normal production and operational conditions, despite a 20% increase in stock price over three days [15] - Hengrui Medicine received approval for clinical trials of two new drugs, HRS-7172 and SHR-A2009, which are innovative treatments for cancer [16]

Core Insights - The competitiveness of the biopharmaceutical industry ultimately reflects the cluster effect [1][11] - The biopharmaceutical industry is a core track of global technological revolution and industrial transformation, serving as a key indicator of regional economic high-quality development [2] Industry Development - The Yangtze River Delta region, centered around Shanghai Zhangjiang and Suzhou BioBAY, has established a first-mover advantage in the biopharmaceutical field due to early policy layouts, dense research resources, and a complete industrial chain [2] - Guangzhou Huangpu District has not lagged despite being a latecomer; it has optimized its policy system, built talent aggregation platforms, and focused on breakthroughs in niche markets, gradually compensating for industrial chain shortcomings [2][12] Key Companies and Innovations - Yunzhou Biotech, founded by Dr. Lan Tian in Huangpu District in 2014, focuses on gene delivery, a critical link between basic research and clinical application [3] - The company developed the world's first intelligent design and ordering platform for gene carriers, integrating over 120 carrier systems and more than 2 million carrier components, significantly lowering the barriers for researchers [4][5] - Yunzhou Biotech has become the world's largest custom gene carrier supplier, serving over 7,000 institutions in more than 130 countries, with a cumulative delivery of over 1 million carriers by September 2024 [5][6] Market Position and Achievements - In 2023, Yunzhou Biotech achieved a valuation of 7 billion, becoming a unicorn and the first biopharmaceutical company in Guangzhou to reach this status [6] - The company has established a full-service capability in the gene drug development chain, including CRO and CDMO services, with its products approved for clinical trials in the U.S. [6][7] Competitive Landscape - Innovation in drug development is a core competitive advantage in the biopharmaceutical industry, with companies like Kangfang Biopharma emerging as leaders in the field [8] - Kangfang Biopharma has developed over 50 innovative drug candidates, with 24 products undergoing clinical trials, and has successfully commercialized 7 first-class new drugs [10] Ecosystem and Collaboration - Huangpu District's "bending overtaking" is not merely the success of a single enterprise but a result of creating a quality industrial ecosystem that fosters collaboration between leading external companies and local enterprises [12] - The presence of major companies like Hengrui Medicine and Nuocheng Jianhua in Huangpu has attracted a network of supporting enterprises, enhancing the regional industrial chain [13][14]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月2日，恒瑞医药发布公告称，公司近日收到国家药品监 督管理局核准签发关于HRS—7172片的《药物临床试验批准通知书》，同意该品单药在携带RAS突变或 扩增的晚期实体瘤患者中开展临床试验。 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3, aimed at treating advanced solid tumors [1] Group 1 - The clinical trial will focus on the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapy in patients with advanced solid tumors [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1]

恒瑞医药(600276.SH)公告，公司收到国家药品监督管理局核准签发关于HRS-7172片的《药物临床试验 批准通知书》，同意本品单药在携带RAS突变或扩增的晚期实体瘤患者中开展临床试验。HRS-7172片 是公司自主研发的新型抗肿瘤小分子抑制剂。 ...

恒瑞医药（600276）(600276.SH)公告，公司收到国家药品监督管理局核准签发关于HRS-7172片的《药 物临床试验批准通知书》，同意本品单药在携带RAS突变或扩增的晚期实体瘤患者中开展临床试验。 HRS-7172片是公司自主研发的新型抗肿瘤小分子抑制剂。 ...